KR20200011957A - 암 치료를 위한 조합 요법 - Google Patents

암 치료를 위한 조합 요법 Download PDF

Info

Publication number
KR20200011957A
KR20200011957A KR1020197037178A KR20197037178A KR20200011957A KR 20200011957 A KR20200011957 A KR 20200011957A KR 1020197037178 A KR1020197037178 A KR 1020197037178A KR 20197037178 A KR20197037178 A KR 20197037178A KR 20200011957 A KR20200011957 A KR 20200011957A
Authority
KR
South Korea
Prior art keywords
cancer
combination
optionally
cell
carcinoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197037178A
Other languages
English (en)
Korean (ko)
Inventor
이홍 장
왕 웨이
이요우 첸
Original Assignee
코테라 바이오사이언스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 코테라 바이오사이언스 인코포레이티드 filed Critical 코테라 바이오사이언스 인코포레이티드
Publication of KR20200011957A publication Critical patent/KR20200011957A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020197037178A 2017-06-02 2018-06-01 암 치료를 위한 조합 요법 Ceased KR20200011957A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2017/086911 2017-06-02
PCT/CN2017/086911 WO2018218633A1 (en) 2017-06-02 2017-06-02 Combination therapies for treating cancers
PCT/US2018/035641 WO2018223022A1 (en) 2017-06-02 2018-06-01 Combination therapies for treating cancers

Publications (1)

Publication Number Publication Date
KR20200011957A true KR20200011957A (ko) 2020-02-04

Family

ID=64454257

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197037178A Ceased KR20200011957A (ko) 2017-06-02 2018-06-01 암 치료를 위한 조합 요법

Country Status (10)

Country Link
US (2) US12076399B2 (enExample)
EP (1) EP3630196A4 (enExample)
JP (1) JP2020522521A (enExample)
KR (1) KR20200011957A (enExample)
CN (1) CN111212662A (enExample)
AU (1) AU2018275118B2 (enExample)
BR (1) BR112019025453A2 (enExample)
CA (1) CA3063743A1 (enExample)
RU (1) RU2019143403A (enExample)
WO (2) WO2018218633A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11395821B2 (en) 2017-01-30 2022-07-26 G1 Therapeutics, Inc. Treatment of EGFR-driven cancer with fewer side effects
WO2018218633A1 (en) 2017-06-02 2018-12-06 Beijing Percans Oncology Co. Ltd. Combination therapies for treating cancers
KR20200108867A (ko) 2018-01-08 2020-09-21 쥐원 쎄라퓨틱스, 인크. G1t38 우수한 투여 요법
IL257225A (en) * 2018-01-29 2018-04-09 Yeda Res & Dev Treatment of sarcoma
WO2019195959A1 (en) 2018-04-08 2019-10-17 Cothera Biosciences, Inc. Combination therapy for cancers with braf mutation
US11633401B2 (en) 2018-07-06 2023-04-25 Memorial Sloan Kettering Cancer Center Combination therapy with MEK inhibitor and CDK4/6 inhibitor to treat pancreatic cancer
EP3836909A4 (en) 2018-08-13 2022-07-27 Beijing Percans Oncology Co. Ltd. BIOMARKERS FOR CANCER THERAPY
AU2020363101A1 (en) * 2019-10-09 2022-05-05 Cothera Bioscience, Inc. Combination therapy for cancers with KRAS mutation
CA3157409A1 (en) * 2019-10-09 2021-04-15 Cothera Bioscience, Inc. Combination therapy for cancers with kras mutation
CN112168828A (zh) * 2020-11-10 2021-01-05 南京医科大学 一种egfr与cdk4/6小分子靶向药组合物及其应用
CN114939168A (zh) * 2022-05-16 2022-08-26 复旦大学 Cdk6抑制剂在制备预防或治疗垂体腺瘤的药物中的应用
CN115029316B (zh) * 2022-06-20 2024-04-30 华中科技大学同济医学院附属协和医院 一种具有放疗敏感和放疗耐受特性的原代宫颈癌细胞系及其构建方法和应用

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5976790A (en) 1992-03-04 1999-11-02 The Regents Of The University Of California Comparative Genomic Hybridization (CGH)
PL181342B1 (pl) 1994-03-17 2001-07-31 Merck Patent Gmbh Jednolancuchowe anty-EGFR Fv i przeciwciala anty-EGFR, czasteczka DNA, sposoby wytwarzania jednolancuchowego przeciwciala anty-EGFR i przeciwciala anty-EGFR oraz kompozycja farmaceutyczna PL PL PL PL PL PL PL
ES2243441T3 (es) 2000-02-15 2005-12-01 Astellas Pharma Inc. Derivados de imidazolio fundidos.
WO2002066058A1 (en) 2001-02-19 2002-08-29 Merck Patent Gmbh Modified anti-egfr antibodies with reduced immunogenicity
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
RU2335507C2 (ru) 2001-06-13 2008-10-10 Генмаб А/С Человеческие моноклональные антитела к рецептору эпидермального фактора роста (egfr), способ их получения и их использование, гибридома, трансфектома, трансгенное животное, экспрессионный вектор
US20060223831A1 (en) 2003-04-15 2006-10-05 Isao Kinoyama Bromide and its crystal
PE20050928A1 (es) 2003-11-21 2005-11-08 Schering Corp Combinaciones terapeuticas de anticuerpo anti-igfr1
DE10355904A1 (de) 2003-11-29 2005-06-30 Merck Patent Gmbh Feste Formen von anti-EGFR-Antikörpern
CA2561516A1 (en) * 2004-03-30 2005-10-13 Pfizer Products Inc. Combinations of signal transduction inhibitors
JPWO2005111213A1 (ja) 2004-05-18 2008-03-27 学校法人 久留米大学 Ｍｙｃ標的遺伝子ｍｉｍｉｔｉｎ
WO2006036941A2 (en) 2004-09-27 2006-04-06 Kosan Biosciences Incorporated Specific kinase inhibitors
ATE461220T1 (de) 2005-11-12 2010-04-15 Lilly Co Eli Anti-egfr-antikörper
JP4806776B2 (ja) 2006-01-27 2011-11-02 国立大学法人 千葉大学 ｃ−ｍｙｃ遺伝子転写抑制因子ＦＩＲのスプライシングバリアント又はイントロン２内の４塩基繰り返し配列による癌検出方法
US7498142B2 (en) 2006-01-31 2009-03-03 Yeda Research And Development Co., Ltd. Methods of identifying combinations of antibodies with an improved anti-tumor activity and compositions and methods using the antibodies
JO3235B1 (ar) 2006-05-26 2018-03-08 Astex Therapeutics Ltd مركبات بيررولوبيريميدين و استعمالاتها
CA2661618A1 (en) 2006-08-25 2008-02-28 Astellas Pharma Inc. Stabilized pharmaceutical composition
AU2007314341B2 (en) 2006-10-31 2013-04-11 Merck Sharp & Dohme Corp. 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors
US7618992B2 (en) 2006-12-29 2009-11-17 Astellas Pharma Inc. Method of treating cancer by co-administration of anticancer agents
WO2009058729A2 (en) 2007-10-29 2009-05-07 Schering Corporation Thiazole carboxamide derivatives and their to treat cancer
ES2456966T3 (es) 2007-11-12 2014-04-24 Takeda Pharmaceutical Company Limited Inhibidores de MAPK/ERK cinasa
WO2009146034A2 (en) 2008-03-31 2009-12-03 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors and methods of use thereof
BRPI0917791B1 (pt) 2008-08-22 2022-03-22 Novartis Ag Compostos de pirrolopirimidina como inibidores de cdk, bem como composição farmacêutica e combinação
US8877445B2 (en) 2008-11-14 2014-11-04 Intelligent Oncotherapeutics, Inc. Methods for identification of tumor phenotype and treatment
WO2010083505A1 (en) 2009-01-19 2010-07-22 The Trustees Of The University Of Pennsylvania Method of treating cancer using a survivin inhibitor
ES2576061T3 (es) 2010-02-25 2016-07-05 Dana-Farber Cancer Institute, Inc. Mutaciones de BRAF que confieren resistencia a inhibidores de BRAF
MX2012011912A (es) 2010-04-13 2012-11-16 Novartis Ag Combinacion que comprende un inhibidor de cinasa 4 dependiente de ciclina o cinasa dependiente de ciclia (cdk4/6) y un inhibidor de mtor para tratar cancer.
US8709419B2 (en) 2010-08-17 2014-04-29 Hoffmann-La Roche, Inc. Combination therapy
JP2014156400A (ja) 2011-05-24 2014-08-28 Astellas Pharma Inc 腫瘍の画像診断用標識誘導体
WO2012167099A1 (en) 2011-06-01 2012-12-06 Baylor College Of Medicine Biomarkers and therapy for cancer
FI20115876A0 (fi) 2011-09-06 2011-09-06 Turun Yliopisto Yhdistelmähoito
WO2013060872A1 (en) 2011-10-27 2013-05-02 Boehringer Ingelheim International Gmbh Anticancer combination therapy
JP2015505668A (ja) 2011-11-16 2015-02-26 オンコメッド ファーマシューティカルズ インコーポレイテッド ヒトｎｏｔｃｈ受容体変異およびその使用
WO2013148649A1 (en) 2012-03-26 2013-10-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Use of survivin antagonists in polyomavirus-related disease
AR091876A1 (es) 2012-07-26 2015-03-04 Novartis Ag Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
JP2016515132A (ja) * 2013-03-14 2016-05-26 ジェネンテック， インコーポレイテッド Ｍｅｋ阻害剤化合物のｈｅｒ３／ｅｇｆｒ阻害剤化合物との組み合わせ及び使用方法
WO2014152950A1 (en) 2013-03-14 2014-09-25 Wake Forest University Health Sciences Methods and compositions for correlating genetic markers with risk of aggressive prostate cancer
MX2015011444A (es) 2013-03-15 2015-12-16 Genentech Inc Composiciones y metodos para el diagnostico y tratamiento del cancer hepatico.
SG11201507730UA (en) * 2013-03-21 2015-10-29 Novartis Ag Combination therapy comprising a b-raf inhibitor and a second inhibitor
US9314460B1 (en) 2013-04-09 2016-04-19 Stc.Unm Method for cancer cell reprogramming
KR101514877B1 (ko) 2013-05-06 2015-04-24 조선대학교산학협력단 ＡＰＥ/Ｒｅｆ -1 및 ＪＡＧ1/Ｎｏｔｃｈ의 대장암 진단용 마커로서의 용도
US20170080093A1 (en) * 2013-10-22 2017-03-23 Tyme, Inc. Tyrosine Derivatives And Compositions Comprising Them
US11013743B2 (en) 2013-12-20 2021-05-25 Biomed Valley Discoveries, Inc. Cancer treatments using combinations of CDK and ERK inhibitors
WO2015150826A1 (en) 2014-04-04 2015-10-08 Astrazeneca Ab Combination of egfr inhibitor and mek inhibitor for use in the treatment of nras mutated cancer
WO2015160868A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc Methods for treating cancer using tor kinase inhibitor combination therapy
ES2686549T3 (es) 2014-06-16 2018-10-18 Worldwide Innovative Network Método para seleccionar una triterapia personalizada para el tratamiento del cáncer
US9446148B2 (en) 2014-10-06 2016-09-20 Mayo Foundation For Medical Education And Research Carrier-antibody compositions and methods of making and using the same
CN113893253A (zh) * 2015-05-22 2022-01-07 普莱希科公司 用于治疗braf-v600相关的疾病的plx-8394或plx-7904
CA2986441A1 (en) * 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
US10668149B2 (en) 2015-06-22 2020-06-02 Janssen Biotech, Inc. Combination therapies for heme malignancies with anti-CD38 antibodies and survivin inhibitors
WO2017019279A1 (en) * 2015-07-27 2017-02-02 Southern Research Institute Methods and compositions to treat cancers involving egfr
ES2761885T3 (es) * 2015-08-28 2020-05-21 Novartis Ag Combinaciones farmacéuticas que comprenden (a) el inhibidor de la cinasa dependiente de ciclina 4/6 (CDK4/6) LEE011 (= ribociclib) y (b) el inhibidor del receptor del factor de crecimiento epidérmico (EGFR) erlotinib, para el tratamiento o la prevención del cáncer
KR20180043835A (ko) * 2015-09-03 2018-04-30 에일러론 테라퓨틱스 인코포레이티드 펩티도미메틱 매크로사이클 및 이의 용도
CA2998472A1 (en) 2015-09-15 2017-03-23 Swedish Health Services Methods and panels of compounds for characterization of glioblastoma multiforme tumors and cancer stem cells thereof
WO2017070475A1 (en) * 2015-10-22 2017-04-27 Merrimack Pharmaceuticals, Inc. Methods of treating cancer by administering a mek inhibitor and a combination of anti-egfr antibodies
US20190017054A1 (en) 2016-01-07 2019-01-17 Luni Emdad Method of modulating survival and stemness of cancer stem cells by mda-9/syntenin (sdcbp)
WO2017143237A1 (en) 2016-02-17 2017-08-24 Acetylon Pharmaceuticals, Inc. Increasing expression of interferon regulated genes with combinatons of histone deacetylase inhibitors and immunomodulatory drugs
TW201813644A (zh) 2016-09-23 2018-04-16 江蘇恆瑞醫藥股份有限公司 酪胺酸激酶抑制劑在製備治療癌症藥物中的用途
WO2018127786A1 (en) 2017-01-06 2018-07-12 Oslo Universitetssykehus Hf Compositions and methods for determining a treatment course of action
CN106822905B (zh) 2017-03-08 2019-05-17 暨南大学 含Survivin抑制剂和IRE1抑制剂的药物及用途
WO2018218633A1 (en) 2017-06-02 2018-12-06 Beijing Percans Oncology Co. Ltd. Combination therapies for treating cancers
US20190292602A1 (en) 2018-03-21 2019-09-26 Dana-Farber Cancer Institute, Inc. Therapeutic treatment of select diffuse large b cell lymphomas exhibiting distinct pathogenic mechanisms and outcomes
WO2019195959A1 (en) 2018-04-08 2019-10-17 Cothera Biosciences, Inc. Combination therapy for cancers with braf mutation
WO2020034061A1 (en) 2018-08-13 2020-02-20 Beijing Percans Oncology Co., Ltd. Biomarkers for cancer therapy
EP3836909A4 (en) 2018-08-13 2022-07-27 Beijing Percans Oncology Co. Ltd. BIOMARKERS FOR CANCER THERAPY
WO2020097901A1 (en) 2018-11-16 2020-05-22 Beijing Percans Oncology Co. Ltd. Biomarkers for cancer therapy

Also Published As

Publication number Publication date
RU2019143403A (ru) 2021-07-13
CA3063743A1 (en) 2018-12-06
AU2018275118A1 (en) 2019-12-19
EP3630196A1 (en) 2020-04-08
BR112019025453A2 (pt) 2020-06-23
WO2018223022A1 (en) 2018-12-06
JP2020522521A (ja) 2020-07-30
EP3630196A4 (en) 2021-02-24
US20200147211A1 (en) 2020-05-14
US20250121057A1 (en) 2025-04-17
RU2019143403A3 (enExample) 2021-10-01
WO2018218633A1 (en) 2018-12-06
US12076399B2 (en) 2024-09-03
CN111212662A (zh) 2020-05-29
AU2018275118B2 (en) 2024-12-19

Similar Documents

Publication Publication Date Title
US20250121057A1 (en) Combination therapies for treating cancers
CN111971062B (zh) 一种抗人pd-1的单克隆抗体制剂、联合用药物及其用途
JP7030750B2 (ja) Ｌａｇ－３に対する抗体分子およびその使用
JP2023030174A (ja) Ｎｋｇ２ｄ、ｃｄ１６、および腫瘍関連抗原に結合するタンパク質
JP2021104025A (ja) Ｔｉｍ−３に対する抗体分子およびその使用
US20230203202A1 (en) Proteins binding nkg2d, cd16 and 5t4
JP2021035962A (ja) がんを治療するための、ｐｄ−１アンタゴニスト及びｖｅｇｆｒ／ｆｇｆｒ／ｒｅｔチロシンキナーゼ阻害剤の組合せ
AU2021284273A1 (en) Antibodies to TIGIT
IL268755B1 (en) Proteins binding her2, nkg2d and cd16
US20250289876A1 (en) Connexin 43 antibodies and use thereof
WO2023165615A1 (en) Combination therapies comprising a kras inhibitor for the treatment of cancer
CN116323657A (zh) 同时靶向PD-L1和TGFβ的双功能分子及其医药用途
CN113842456B (zh) 一种抗人4-1bb的单克隆抗体制剂及其用途
HK40029586A (en) Combination therapies for treating cancers
HK40042791A (en) Connexin 43 antibodies and use thereof
JP2014124153A (ja) 非誘導体型ｌｐａに対して作成された抗ｌｐａ特異抗体

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20191216

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210526

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230428

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20230703

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230428

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I